These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2956111)
1. Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma. Landström M; Tomić R; Damber JE Eur Urol; 1987; 13(3):203-6. PubMed ID: 2956111 [TBL] [Abstract][Full Text] [Related]
2. Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology. Damber JE; Bergh A; Landström M; Tomić R J Urol; 1991 Jun; 145(6):1283-7. PubMed ID: 1827847 [TBL] [Abstract][Full Text] [Related]
3. Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer. Anderström C Cancer Chemother Pharmacol; 1994; 35 Suppl():S97-100. PubMed ID: 7994797 [TBL] [Abstract][Full Text] [Related]
4. Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma. Daehlin L; Bergh A; Damber JE Urol Res; 1987; 15(3):169-72. PubMed ID: 3629752 [TBL] [Abstract][Full Text] [Related]
5. Blood flow in the Dunning R3327H rat prostatic adenocarcinoma; effects of oestradiol and testosterone. Daehlin L; Damber JE Urol Res; 1986; 14(2):113-7. PubMed ID: 3727214 [TBL] [Abstract][Full Text] [Related]
6. Antiestrogens do not counteract the inhibitory effect of estradiol-17 beta on the growth of the Dunning R3327 prostatic adenocarcinoma. Landström M; Damber JE; Bergh A; Tomic R; Carlsson-Bostedt L; Stigbrand T Prostate; 1988; 12(4):287-98. PubMed ID: 3393491 [TBL] [Abstract][Full Text] [Related]
7. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma. Sylvester PW; Ip MM Prostate; 1987; 10(1):57-67. PubMed ID: 3822918 [TBL] [Abstract][Full Text] [Related]
8. Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats. Rosenberg CA; Hrushesky WJ; Langevin T; Kennedy BJ Oncology; 1985; 42(1):48-54. PubMed ID: 3969257 [TBL] [Abstract][Full Text] [Related]
9. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. Seifter EJ; Bunn PA; Cohen MH; Makuch RW; Dunnick NR; Javadpour N; Bensimon H; Eddy JL; Minna JD; Ihde DC J Clin Oncol; 1986 Sep; 4(9):1365-73. PubMed ID: 2943877 [TBL] [Abstract][Full Text] [Related]
10. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats. Van Ginckel R; De Coster R; Wouters W; Vanherck W; van der Veer R; Goeminne N; Jagers E; Van Cauteren H; Wouters L; Distelmans W Prostate; 1990; 16(4):313-23. PubMed ID: 2371176 [TBL] [Abstract][Full Text] [Related]
11. Experimental treatment of prostatic cancer by intermittent hormonal therapy. Trachtenberg J J Urol; 1987 Apr; 137(4):785-8. PubMed ID: 3560348 [TBL] [Abstract][Full Text] [Related]
12. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study. Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830 [TBL] [Abstract][Full Text] [Related]
13. [Combination with medroxyprogesterone acetate and chemotherapy making possible complete removal of uterine corpus carcinoma]. Tajima H; Okada T; Fujimori Y; Tomioka Y; Hirano M; Yoshida T; Ikeda S; Hata T Gan To Kagaku Ryoho; 1989 Jul; 16(7):2461-4. PubMed ID: 2526620 [TBL] [Abstract][Full Text] [Related]
14. Effect of medroxyprogesterone acetate on the growth of mouse transplanted tumors: relation with hormone sensitivity. Formelli F; Ronchi E; Di Fronzo G Anticancer Res; 1985; 5(3):313-9. PubMed ID: 3160299 [TBL] [Abstract][Full Text] [Related]
15. Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer. Kontturi M; Sotarauta M; Tammela T; Lukkarinen O; Romppainen ML; Gröhn P Eur Urol; 1988; 15(1-2):43-7. PubMed ID: 2975221 [TBL] [Abstract][Full Text] [Related]
16. Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study. Anderström C; Eddeland A; Folmerz P; Hansson R; Milles S; Zachrisson B Eur Urol; 1995; 27(4):301-5. PubMed ID: 7656906 [TBL] [Abstract][Full Text] [Related]
17. Sequential alternating medroxyprogesterone acetate and epirubicin in the treatment of advanced breast cancer. Smith JA; Green MD; Russell IS; Collins JP Aust N Z J Surg; 1989 Nov; 59(11):869-72. PubMed ID: 2530970 [TBL] [Abstract][Full Text] [Related]
18. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats]. Tomura A; Kuroiwa S; Okada M; Abe F Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363 [TBL] [Abstract][Full Text] [Related]
19. Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone. Bezwoda WR Br J Urol; 1990 Aug; 66(2):196-201. PubMed ID: 2143960 [TBL] [Abstract][Full Text] [Related]
20. Effects of 6-methylene progesterone on growth, morphology, and blood flow of the Dunning R3327 prostatic adenocarcinoma. Damber JE; Bergh A; Daehlin L; Petrow V; Landström M Prostate; 1992; 20(3):187-97. PubMed ID: 1574466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]